@article{815b0fda21f34fd78f9d40692a184b6f,
title = "Combined effects of antenatal receipt of influenza vaccine by mothers and pneumococcal conjugate vaccine receipt by infants: Results from a randomized, blinded, controlled trial",
abstract = "A 2 × 2 factorial trial was performed to determine the efficacy of antennal influenza vaccination of mothers plus pneumococcal conjugate vaccination of their infants against respiratory illness during early infancy. The efficacy of trivalent inactivated influenza vaccine (TIV; delivered to mothers) plus 7-valent pneumococcal vaccine (PCV7; delivered to infants) was higher than the efficacy of TIV alone or PCV7 alone. During the period of the study in which influenza was circulating, the efficacy of TIV plus PCV7 was 72.4% (95% confidence interval, 30.2%-89.1%) against febrile respiratory illness and 66.4% (95% CI, 14.3%-86.9%) against medically attended acute respiratory illness. Clinical Trials registration NCT00142389.",
keywords = "Influenza vaccine, influenza-like illness, pneumococcal conjugate vaccine, pregnancy",
author = "Omer, {Saad B.} and Khalequ Zaman and Eliza Roy and Arifeen, {Shams E.} and Rubhana Raqib and Laila Noory and Katherine Seib and Breiman, {Robert F.} and Steinhoff, {Mark C.}",
note = "Funding Information: Financial support. This work was supported by the Bill and Melinda Gates Foundation, through a cooperative agreement (HRN-A-0096-90006-00) with the US Agency for International Development, the Department of Health and Human Services, the National Vaccine Program Office, Wyeth Pharmaceuticals, the Thrasher Research Fund, Aventis Pasteur, the International Centre for Diarrheal Disease Research, and the Bloomberg School of Public Health at Johns Hopkins University. Funding Information: Potential conflicts of interest. M. C. S. served as a consultant for No-vartis, GSK, and Merck during the year before manuscript submission. In 2009, S. B. O. was awarded the Maurice R. Hilleman Early-Stage Career Investigator Award by the National Foundation for Infectious Diseases (NFID). The award was funded by an unrestricted educational grant to the NFID from Merck; however, S. B. O. had no direct interaction with Merck. All other authors report no potential conflicts.",
year = "2013",
month = apr,
day = "1",
doi = "10.1093/infdis/jit003",
language = "English (US)",
volume = "207",
pages = "1144--1147",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",
}